Based on the results of KEYNOTE-826, pembrolizumab in combination with platinum/paclitaxel and bevacizumab was approved as a first-line treatment regimen for recurrent/metastatic cervical cancer with significant PD-L1 expression [86]. This evidence concerns the gene CD274 and cervical cancer.